Company Filing History:
Years Active: 1999
Title: The Innovations of Christopher Robin Dalton
Introduction
Christopher Robin Dalton is an accomplished inventor based in Cincinnati, Ohio. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of depression. His innovative approach has led to the development of novel compounds that show promise in enhancing mental health.
Latest Patents
Dalton holds a patent for 3-phenyl-1,4-dialkyl-1,2,4-triazolium salts and their use in treating depression. This invention relates to the administration of these novel compounds, which are characterized by the formula ##STR1##, where R can be halogen, trifluoromethyl, C1-4 lower alkyl, or C1-4 lower alkoxy. This patent represents a significant advancement in the search for effective treatments for depressive disorders.
Career Highlights
Throughout his career, Dalton has been associated with Hoechst Marion Roussel, a company known for its commitment to pharmaceutical innovation. His work has not only contributed to the company's portfolio but has also had a lasting impact on the field of mental health treatment.
Collaborations
Dalton has collaborated with notable colleagues, including John M. Kane and John H. Kehne. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and the advancement of research in their respective fields.
Conclusion
Christopher Robin Dalton's contributions to the field of pharmaceuticals, particularly in the treatment of depression, highlight his innovative spirit and dedication to improving mental health. His patent for 3-phenyl-1,4-dialkyl-1,2,4-triazolium salts is a testament to his impactful work.